Literature DB >> 26603719

Patients with type 1 Gaucher disease in Spain: A cross-sectional evaluation of health status.

Pilar Giraldo1, Jordi Pérez-López2, Ramiro Núñez3, Rafael Fernández de la Puebla4, Elisa Luño5, Salvador Saura-Grau6, Juan Carlos Bureo7, Sylvia Plaza8, Javier de la Serna9.   

Abstract

A multicentre, cross-sectional epidemiological survey was conducted to describe the health status of patients with type 1 Gaucher disease (GD1) in Spain. Patient data were collected retrospectively from clinical records. Therapeutic goals for seven clinical parameters were chosen as primary outcome measures. 108 GD1 patients (mean age 44.8 years; 53% male) were recruited from 28 hospitals. Ninety-five patients (88%) were receiving treatment for GD1. Hemoglobin concentration was the therapeutic goal with the highest level of achievement, being met by 105 of 108 patients (97%), followed by the goals for liver volume (86/98 patients; 88%), spleen volume (67/77 patients; 87%) and platelet count (81/108 patients; 75%). The goal for bone mineral density (BMD) was met by 48 of 75 patients (64%), and the goal for quality of life was met by 65 of 103 patients (63%). Bone pain was the parameter with the lowest level of achievement (goal met by 50/94 patients; 53%). The clinical information most often missing from patient records was the BMD Z-score (missing for 31% of patients). These data suggest that most Spanish GD1 patients have good control over hematological and visceral parameters, but there is a need to improve monitoring and treatment of GD-related bone disease.
Copyright © 2015. Published by Elsevier Inc.

Entities:  

Keywords:  Bone disease; Spain; Therapeutic goals; Type 1 Gaucher disease

Mesh:

Year:  2015        PMID: 26603719     DOI: 10.1016/j.bcmd.2015.10.001

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  7 in total

1.  Gene variants of osteoprotegerin, estrogen-, calcitonin- and vitamin D-receptor genes and serum markers of bone metabolism in patients with Gaucher disease type 1.

Authors:  Anca Zimmermann; Radu A Popp; Heidi Rossmann; Simona Bucerzan; Ioana Nascu; Daniel Leucuta; Matthias M Weber; Paula Grigorescu-Sido
Journal:  Ther Clin Risk Manag       Date:  2018-10-24       Impact factor: 2.423

Review 2.  Gaucher Disease in Bone: From Pathophysiology to Practice.

Authors:  Derralynn Hughes; Peter Mikosch; Nadia Belmatoug; Francesca Carubbi; TimothyM Cox; Ozlem Goker-Alpan; Andreas Kindmark; PramodK Mistry; Ludger Poll; Neal Weinreb; Patrick Deegan
Journal:  J Bone Miner Res       Date:  2019-06-24       Impact factor: 6.741

3.  Accuracy of chitotriosidase activity and CCL18 concentration in assessing type I Gaucher disease severity. A systematic review with meta-analysis of individual participant data.

Authors:  Tatiana Raskovalova; Patrick B Deegan; Pramod K Mistry; Elena Pavlova; Ruby Yang; Ari Zimran; Juliette Berger; Céline Bourgne; Bruno Pereira; José Labarère; Marc G Berger
Journal:  Haematologica       Date:  2021-02-01       Impact factor: 9.941

Review 4.  Novel Management and Screening Approaches for Haematological Complications of Gaucher's Disease.

Authors:  Pilar Giraldo; Marcio Andrade-Campos
Journal:  J Blood Med       Date:  2021-12-07

Review 5.  Patient and observer reported outcome measures to evaluate health-related quality of life in inherited metabolic diseases: a scoping review.

Authors:  Carlota Pascoal; Sandra Brasil; Rita Francisco; Dorinda Marques-da-Silva; Agnes Rafalko; Jaak Jaeken; Paula A Videira; Luísa Barros; Vanessa Dos Reis Ferreira
Journal:  Orphanet J Rare Dis       Date:  2018-11-28       Impact factor: 4.123

6.  Health-related quality of life in children and adolescents living with Gaucher disease and their parents.

Authors:  Eduardo Remor; Antonio Baldellou
Journal:  Health Psychol Behav Med       Date:  2018-04-12

7.  Upregulation of Cytotoxic T-cells in pediatric patients with Gaucher disease.

Authors:  Asmaa M Zahran; Khaled Saad; Khalid I Elsayh; Madleen Adel A Abdou; Amir M Abo-Elgheet; Esraa M Eloseily; Shaimaa M Khalaf; Shabaan Sror; Faisal-Alkhateeb Ahmad; Amira Elhoufey; Aliaa Ghandour; Naglaa S Osman
Journal:  Sci Rep       Date:  2022-03-23       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.